Barcelona hospital tests new drug for end-stage renal disease patients
Barcelona's Vall d'Hebron hospital tested the efficacy of a drug on end-stage renal disease patients with hyperactivated immune systems. Imlifidase can eliminate antibodies and help prevent organ rejection in patients who would otherwise remain on dialysis for years.